General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Dividend | Date |
---|---|
0.52213 | 2024-03-21 |
0.73388 | 2023-12-20 |
0.82888 | 2023-09-26 |
0.50868 | 2023-06-07 |
0.63067 | 2023-03-23 |
0.83 | 2022-12-13 |
Split | Date |
---|---|
2 : 1 | 2005-06-09 |
About Destiny Tech100
Destiny's flagship offering, the Destiny Tech100, will be a publicly-listed portfolio of 100 of the top venture-backed private technology companies, providing everyday investors access to many of the world's most exciting private businesses.
Current Tech100 holdings include: SpaceX, OpenAI, Epic Games, Discord, Superhuman, and Stripe. For a comprehensive list of holdings, visit the fund website www.destiny.xyz/tech100.
Image for Press Release 1867753
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327776952/en/
If you want more alerts how you are doing, join my free telegram channel..
$PTC Therapeutics(PTCT.US)$ Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
$PTC Therapeutics(PTCT.US)$ Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
$IWM what about that hourly death cross. If it happens?
This is a dirty little tactic institutions use to manipulate price!
There seems to be a correlation between the price movement of most equities and the 29th and 30th of each month, particularly January, April, July and October. If your charting look for those dates on each month and draw a trend line on the daily close on those dates and see what you find. Institutions favor prices around those dates. Look up Citigroup global markets and 424(b) they sell those to institutional investors and institutions run price to their favor on the named equity on the 424(b).
This thing dropping again tomorrow or?
This ETF is being shorted into the ground. Look at massive open interest for put options on June 18th. Those numbers arenβt normal for this ETF. Even the $SPY doesnβt see these mind numbing put options.